The use of i2b2 for determining feasibility of clinical studies and clinical trials, focusing on the use of i2b2 in networks across the country, and novel approaches to allowing investigators to perform feasibility studies using i2b2-based client tools.
Presentations:
| SHRINE Update | Douglas MacFadden |
| Nich Wattanasin | |
| Jack London | |
| Kavi Wagholikar |
